Surgery Partners Enters Market Well Below Expected Range
Surgery Partners entered the market on Thursday in its initial public offering priced under the expected range.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 244Sarepta Makes Headway With Phase 2 Program
Sarepta Therapeutics announced additional clinical efficacy and safety data from its Phase 2b program of eteplirsen in patients with Duchenne muscular dystrophy.
Mirna Therapeutics Sets IPO Price
ThinkstockMirna Therapeutics has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). Some 6.25 million shares are being offered, with an overallotment option for…
Dyax Wins Positive Opinion for European Orphan Designation
Dyax announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending DX-2930.
Civitas Readies for Secondary Offering
Selling stockholders are offering 3 million Civitas Solutions shares in a secondary offering valued up to more than $84 million.
2 Deutsche Bank Health Care Focus Stocks Have Big Upside Potential
A new report from Deutsche Bank makes the case that the selling in health care stocks is way overdone, and the proverbial baby is being tossed out with the bath water.
DaVita Eyes Expansion Into Brazil
DaVita HealthCare Partners announced that it will be expanding its footprint in emerging markets by beginning operations in Brazil.
Ceres Scores With Licensing Agreement
Ceres announced that KWS SAAT SE, a global seed developer with operations in over 70 counties, will evaluate its Persephone bioinformatics technology under a license agreement.
CytomX Therapeutics Sets Terms for IPO
More than 6 million CytomX shares are expected to price in the range of $14 to $16 in an IPO valued up to more than $122 million.
Why Oppenheimer Sees Community Health Worth Almost Twice as Much
Despite a declining health care sector of late, one key analyst sees potential in Community Health Systems.
Key Analyst Sees Opportunity in Diagnostics Sell-Off
The unexpected reimbursement rate proposals by the Center for Medicaid hit the diagnostic sector on Monday.
Independent Research Sees 3 Top Health and Biotech Stocks as Oversold
Independent research firm Argus has reviews of three of health care picks from its own Focus List in which it still sees significant upside ahead.
Novavax Rekindles Positive Momentum With RSV and Gates Grant
Novavax has announced positive top-line data from a Phase 2 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate to protect infants via maternal immunization.
Esperion Update Not Enough for Investors
Esperion plans to conduct multiple Phase 3 clinical trials that will separately evaluate patients with statin intolerance.
Why Argus Thinks Now Is the Time to Buy Vertex
Argus has been waiting for a better valuation to upgrade Vertex Pharmaceuticals, and the recent weakness in the stock price has given the firm the opportunity.